Trial ID or NCT#

NCT01707264

Status

NOT RECRUITING

Purpose

Dose escalation study to determine the maximum tolerated dose of NEOD001 in approximately 30 subjects with AL amyloidosis. Expansion phase to evaluate safety, efficacy and pharmacokinetics of NEOD001 in 25 additional subjects at the maximum tolerated dose.

Official Title

A Phase 1/2, Open Label, Dose Escalation Study of Intravenous Administration of Single Agent NEOD001 in Subjects With Light Chain (AL) Amyloidosis

Eligibility Criteria

Ages Eligible for Study: Older than 18 Years
Sexes Eligible for Study: All
Accepts Healthy Volunteers: No

Investigator(s)

Michaela Liedtke
Hematologist, Medical oncologist, Multiple myeloma specialist, Leukemia specialist
Associate Professor of Medicine (Hematology) at the Stanford University Medical Center
Steven Coutre
Hematologist, Medical oncologist, Leukemia specialist, Multiple myeloma specialist
Professor of Medicine (Hematology) at the Stanford University Medical Center
Rondeep Brar
Hematologist, Leukemia specialist, Medical oncologist
Clinical Assistant Professor, Medicine - Hematology

Contact us to find out if this trial is right for you.

CONTACT

Ying Hao
(650) 723-0646